Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Psychiatry
Volume 2011, Article ID 246820, 4 pages
http://dx.doi.org/10.1155/2011/246820
Case Report

Treatment Complexities of a Young Woman Suffering Psychosis and Pituitary Adenoma

1Inpatient Psychiatry, Jewish General Hospital, 3755 Cote St. Catherine Road, No. 542A, Montreal, QC, Canada H3T 1E2
2Department of Psychiatry, McGill University, Montreal, QC, Canada H3A 2T5
3Department of Psychology, Concordia University, Montreal, QC, Canada H4B 1R6

Received 12 August 2011; Accepted 11 September 2011

Academic Editor: J. S. Brar

Copyright © 2011 Maxine Sigman and Kate Drury. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. K. Pal and W. A. Sarino, “Effect of risperidone on prolactinoma growth in a psychotic woman,” Psychosomatic Medicine, vol. 62, no. 5, pp. 736–738, 2000. View at Google Scholar · View at Scopus
  2. H. Y. Meltzer and V. S. Fang, “The effect of neuroleptics on serum prolactin in schizophrenic patients,” Archives of General Psychiatry, vol. 33, no. 3, pp. 279–286, 1976. View at Google Scholar · View at Scopus
  3. L. Citrome, “Current guidelines and their recommendations for prolactin monitoring in psychosis,” Journal of Psychopharmacology, vol. 22, no. 2, pp. 90–97, 2008. View at Publisher · View at Google Scholar · View at Scopus
  4. World Federation for Mental Health, “The impact of physical health problems for persons with severe mental disorders,” in The Relationship between Physical and Mental Health: Co-Occurring Disorders, 2004. View at Google Scholar
  5. C. Sebastian and D. Beer, “Physical health problems in schizophrenia and other serious mental illnesses,” Journal of Psychiatric Intensive Care, vol. 3, pp. 101–111, 2007. View at Google Scholar
  6. S. Brown, H. Inskip, and B. Barraclough, “Causes of the excess mortality of schizophrenia,” British Journal of Psychiatry, vol. 177, pp. 212–217, 2000. View at Publisher · View at Google Scholar · View at Scopus
  7. L. M. Koran, Y. Sheline, K. Imai et al., “Medical disorders among patients admitted to a public sector psychiatric inpatient unit,” Psychiatric Services, vol. 53, no. 12, pp. 1623–1625, 2002. View at Publisher · View at Google Scholar · View at Scopus
  8. R. Sandyk, M. Bergsneider, and R. P. Iacono, “Acute psychosis in a woman with a prolactinoma,” International Journal of Neuroscience, vol. 37, no. 3-4, pp. 187–190, 1987. View at Google Scholar · View at Scopus
  9. K. Melkersson and A. L. Hulting, “Prolactin-secreting pituitary adenoma in neuroleptic treated patients with psychotic disorder,” European Archives of Psychiatry and Clinical Neuroscience, vol. 250, no. 1, pp. 6–10, 2000. View at Google Scholar · View at Scopus
  10. A. Boyd, “Bromocriptine and psychosis: a literature review,” Psychiatric Quarterly, vol. 66, no. 1, pp. 87–95, 1995. View at Publisher · View at Google Scholar · View at Scopus
  11. P. E. Frye, S. F. Pariser, M. H. Kim, and R. W. O'Shaughnessy, “Bromocriptine associated with symptom exacerbation during neuroleptic treatment of schizoaffective schizophrenia,” Journal of Clinical Psychiatry, vol. 43, no. 6, pp. 252–253, 1982. View at Google Scholar · View at Scopus
  12. S. C. Chang, C. H. Chen, and M. L. Lu, “Cabergoline-induced psychotic exacerbation in schizophrenic patients,” General Hospital Psychiatry, vol. 30, no. 4, pp. 378–380, 2008. View at Publisher · View at Google Scholar · View at Scopus
  13. J. Walters and I. Jones, “Clinical questions and uncertainty—prolactin measurement in patients with schizophrenia and bipolar disorder,” Journal of Psychopharmacology, vol. 22, no. 2, pp. 82–89, 2008. View at Publisher · View at Google Scholar · View at Scopus
  14. J. A. Lieberman, “Dopamine partial agonists: a new class of antipsychotic,” CNS Drugs, vol. 18, no. 4, pp. 251–267, 2004. View at Publisher · View at Google Scholar · View at Scopus
  15. M. J. Dunkley and M. A. Reveley, “Successful treatment of refractory schizophrenia with combined olanzapine and quetiapine in a patient with a prolactin secreting pituitary microadenoma,” Journal of Psychopharmacology, vol. 19, no. 1, pp. 97–101, 2005. View at Publisher · View at Google Scholar · View at Scopus